INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
NASDAQ:IART - Nasdaq - US4579852082 - Common Stock - Currency: USD
Taking everything into account, IART scores 3 out of 10 in our fundamental rating. IART was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While IART is still in line with the averages on profitability rating, there are concerns on its financial health. IART is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
IART had positive earnings in the past year.
In the past year IART had a positive cash flow from operations.
Of the past 5 years IART 4 years were profitable.
Each year in the past 5 years IART had a positive operating cash flow.
1.2 Ratios
IART has a better Return On Assets (-0.71%) than 71.66% of its industry peers.
IART has a better Return On Equity (-1.90%) than 72.19% of its industry peers.
IART has a better Return On Invested Capital (4.48%) than 76.47% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IART is in line with the industry average of 7.89%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.71% | ||
| ROE | -1.9% | ||
| ROIC | 4.48% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
Looking at the Operating Margin, with a value of 10.34%, IART is in the better half of the industry, outperforming 77.54% of the companies in the same industry.
IART's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 58.47%, IART perfoms like the industry average, outperforming 56.68% of the companies in the same industry.
In the last couple of years the Gross Margin of IART has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.34% | ||
| PM (TTM) | N/A | ||
| GM | 58.47% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IART is destroying value.
The number of shares outstanding for IART has been reduced compared to 1 year ago.
Compared to 5 years ago, IART has less shares outstanding
The debt/assets ratio for IART is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.15, we must say that IART is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IART (1.15) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.81 indicates that IART is somewhat dependend on debt financing.
The Debt to Equity ratio of IART (0.81) is worse than 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.15 |
ROIC/WACC0.61
WACC7.4%
2.3 Liquidity
IART has a Current Ratio of 1.21. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.21, IART is not doing good in the industry: 82.89% of the companies in the same industry are doing better.
IART has a Quick Ratio of 1.21. This is a bad value and indicates that IART is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.72, IART is doing worse than 89.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.84%.
IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
The Revenue has been growing slightly by 6.19% in the past year.
The Revenue has been growing slightly by 1.20% on average over the past years.
EPS 1Y (TTM)-16.84%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-25.45%
Revenue 1Y (TTM)6.19%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%3.74%
3.2 Future
The Earnings Per Share is expected to grow by 3.38% on average over the next years.
IART is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.92% yearly.
EPS Next Y-10.77%
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
EPS Next 5YN/A
Revenue Next Year3.34%
Revenue Next 2Y3.88%
Revenue Next 3Y3.92%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IART is valuated cheaply with a Price/Earnings ratio of 5.59.
97.86% of the companies in the same industry are more expensive than IART, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.28. IART is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 5.40, which indicates a rather cheap valuation of IART.
Based on the Price/Forward Earnings ratio, IART is valued cheaper than 98.40% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, IART is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.59 | ||
| Fwd PE | 5.4 |
4.2 Price Multiples
95.19% of the companies in the same industry are more expensive than IART, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8.13 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.52
+0.27 (+2.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners96.59%
Inst Owner Change9.1%
Ins Owners3.32%
Ins Owner Change2.07%
Market Cap1.05B
Analysts54.44
Price Target17.05 (26.11%)
Short Float %9.21%
Short Ratio4.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.18%
Min EPS beat(2)-6.76%
Max EPS beat(2)11.12%
EPS beat(4)2
Avg EPS beat(4)1.7%
Min EPS beat(4)-6.76%
Max EPS beat(4)11.12%
EPS beat(8)3
Avg EPS beat(8)2.41%
EPS beat(12)5
Avg EPS beat(12)3.04%
EPS beat(16)8
Avg EPS beat(16)4.75%
Revenue beat(2)0
Avg Revenue beat(2)-2.05%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)-1.58%
Revenue beat(4)0
Avg Revenue beat(4)-1.38%
Min Revenue beat(4)-2.51%
Max Revenue beat(4)-0.64%
Revenue beat(8)0
Avg Revenue beat(8)-1.35%
Revenue beat(12)1
Avg Revenue beat(12)-1.19%
Revenue beat(16)3
Avg Revenue beat(16)-0.84%
PT rev (1m)-17.02%
PT rev (3m)-36.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-24.6%
EPS NY rev (1m)0.05%
EPS NY rev (3m)-8.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.59 | ||
| Fwd PE | 5.4 | ||
| P/S | 0.65 | ||
| P/FCF | N/A | ||
| P/OCF | 10.26 | ||
| P/B | 0.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.13 |
EPS(TTM)2.42
EY17.9%
EPS(NY)2.51
Fwd EY18.54%
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)1.32
OCFY9.74%
SpS20.9
BVpS19.61
TBVpS-9.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.71% | ||
| ROE | -1.9% | ||
| ROCE | 5.36% | ||
| ROIC | 4.48% | ||
| ROICexc | 4.91% | ||
| ROICexgc | 24.71% | ||
| OM | 10.34% | ||
| PM (TTM) | N/A | ||
| GM | 58.47% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexcg growth 3Y-1.99%
ROICexcg growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 86.65% | ||
| Cap/Sales | 7.87% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 32.45% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 1.15 |
F-Score5
WACC7.4%
ROIC/WACC0.61
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.84%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-25.45%
EPS Next Y-10.77%
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
EPS Next 5YN/A
Revenue 1Y (TTM)6.19%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%3.74%
Revenue Next Year3.34%
Revenue Next 2Y3.88%
Revenue Next 3Y3.92%
Revenue Next 5YN/A
EBIT growth 1Y-33.28%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year16.37%
EBIT Next 3Y9.92%
EBIT Next 5YN/A
FCF growth 1Y-112.75%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-58.45%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%